ArborGen Holdings (ARB) H2 2025 earnings summary

Executive summary

• Revenue declined 7% year-over-year to $63.2m, with seedling unit sales down 11% to 328m units and advanced genetics comprising 45% of sales.

• Net loss after tax widened to $(21.5)m, including a non-cash $21.8m impairment of intangible assets.

• Adjusted US GAAP EBITDA was $8.8m, in line with guidance but below the prior year.

• Continued growth in Brazil offset by persistent headwinds in the US South, with operational and market challenges impacting results.

• Strategic investments in production capacity and R&D, including acquisition of a new nursery in Brazil and expansion of US container capacity.

Financial highlights

• Revenue: $63.2m (down from $67.7m year-over-year).

• Gross profit: $18.2m (down from $24.0m year-over-year).

• Net loss after tax: $(21.5)m, compared to $(0.2)m prior year, driven by a $21.8m intangible asset impairment.

• Adjusted US GAAP EBITDA: $8.8m (down from $12.8m year-over-year), with $2.4m in one-off items including a $2.2m gain on sale of the in vitro business.

• Net debt increased to $20.9m from $14.4m, reflecting capex and acquisitions.

Outlook and guidance

• Anticipated improvement in revenue and gross margin as macro pressures ease, especially in the US.

• Brazil volumes expected to grow with expanded production and a shift to protected genetics, though excess capacity may impact pricing.

• US market conditions expected to remain weak until at least 2026, but some growth expected from increased sales activity and higher value products.

• Continued investment in new product development and expansion of container seedling capacity.

• Positioned to benefit from emerging carbon market opportunities.